Treatment of Depression in Patients with Concomitant Cardiac Disease

Progress in Cardiovascular Diseases

Volumn 58, Issue 5, 2016, Pages 514-528

  Teply, Robyn M ^a   Packard, Kathleen A ^a   White, Nicole D ^a   Hilleman, Daniel E ^a   DiNicolantonio, James J ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

Antidepressant; Arrhythmia; Heart failure; Hypertension; Ischemic heart disease

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLONIDINE; CLOPIDOGREL; DESVENLAFAXINE; DIURETIC AGENT; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; METOPROLOL; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NIFEDIPINE; NORTRIPTYLINE; OMEPRAZOLE; PAROXETINE; PLACEBO; PROPAFENONE; PROPRANOLOL; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL; WARFARIN; CARDIOVASCULAR AGENT;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ATRIAL FIBRILLATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DOSE RESPONSE; DRUG CHOICE; DRUG CLEARANCE; DRUG COMPETITION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EDEMA; ELEVATED BLOOD PRESSURE; FAINTNESS; HEART ARRHYTHMIA; HEART BLOCK; HEART DISEASE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPONATREMIA; ISCHEMIC HEART DISEASE; MAJOR DEPRESSION; MORBIDITY; MORTALITY; NAUSEA; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PSYCHOTHERAPY; QT INTERVAL; QT PROLONGATION; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TACHYCARDIA; THROMBOCYTE AGGREGATION INHIBITION; TORSADE DES POINTES; WEIGHT GAIN; WEIGHT REDUCTION; AFFECT; CARDIOVASCULAR SYSTEM; DRUG EFFECTS; DRUG INTERACTION; HEART DISEASES; PATHOPHYSIOLOGY; PATIENT SELECTION; POLYPHARMACY; PSYCHOLOGY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

AFFECT; ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR SYSTEM; COMORBIDITY; DEPRESSION; DRUG INTERACTIONS; HEART DISEASES; HUMANS; PATIENT SELECTION; POLYPHARMACY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84951811756     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2015.11.003     Document Type: Review

References (158)

1. Centers for Disease Control and Prevention fast stats [Accessed September 3, 2014]. http://www.cdc.gov/nchs/fastats/depression.htm.
2. Joynt K.E., Whellan D.J., O'Connor C.M. Depression and cardiovascular disease: mechanisms of interaction. Biol Psychiatry 2003, 54(3):248-261.
3. Lichtman J.H., Froelicher E.S., Blumenthal J.A., et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations. Circulation 2014, 129(12):1350-1369.
4. Jiang W., Kuchibhatla M., Clary G., et al. Relationship between depressive symptoms and long-term mortality in patients with heart failure. Am Heart J 2007, 154:102-108.
5. Junger J., Schellberg D., Muller-Tasch T., et al. Depression increasingly predicts mortality in the course of congestive heart failure. Eur J Heart Fail 2005, 7:261-267.
6. Freedland K.E., Rich M.W., Skala J.A., et al. Prevalence of depression in hospitalized patients with congestive heart failure. Psychosom Med 2003, 65:119-128.
7. Alvarez W., Pickworth K.K. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy 2003, 23(6):754-771.
8. Serebruany V.L., O'Connor C.M., Gurbel P.A. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. Am J Cardiol 2001, 87:1398-1400.
9. Hummel J., Westphal S., Weber-Hamann B., et al. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial. J Clin Psychiatry 2011, 72(7):885-891.
10. Sala M., Lazzaretti M., De Vidovich G.D., et al. Electrophysiological changes of cardiac function during antidepressant treatment. Ther Adv Cardiovasc Dis 2009, 3(1):29-43.
11. Glassman A., Shapiro P.A., Ford D.E., et al. Cardiovascular health and depression. J Psychiatr Pract 2003, 9:409-421.
12. Roose S.P., Laghrissi-Thode F., Kennedy J.S., et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998, 270(4):287-291.
13. Nelson J.C., Kennedy J.S., Pollock B.G., et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry 1999, 156:1024-1028.
14. Jain A.K., Kaplan R.A., Gadde K.M., et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002, 10(10):1049-1056.
15. Anderson J.W., Greenway F.L., Fujioka K., et al. Bupropion SR enhances weight loss: a 48 week double-blind, placebo controlled trial. Obes Res 2002, 7(10):633-641.
16. Vieweg W.V., Wood M.A. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics 2004, 45(5):371-377.
17. Glassman K.H., Walsh B.T., Roose S.P., et al. Factors related to orthostatic hypotension associated with tricyclic antidepressants. J Clin Psychiatry 1982, 43(5):35-38.
18. Roose S.P., Glassman A.H., Giardina E.G.V., et al. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987, 44:273-275.
19. Glassman A.H., Preud'homme X.A. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993, 54(2, Suppl.):16-22.
20. Pollock B.G., Perel J.M., Paradis C.F., Fasiczka A.L., Reynolds C.F. Metabolic and physiologic consequences of nortriptyline treatment in the elderly. Psychopharmacol Bull 1994, 30(2):145-150.
21. Olusi S.O., Fido A.A. Serum lipid concentrations in patients with major depressive disorder. Biol Psychiatry 1996, 11(40):1128-1131.
22. Kopf D., Westphal S., Luley C.W., et al. Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J Clin Psychopharmacol 2004, 5(24):527-531.
23. Rudorfer M.V., Manji H.K., Potter W.Z. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994, 10(1):18-46.
24. Serretti A., Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010, 71(10):1259-1272.
25. Lexicomp Online Lexi-Drugs Online 2014, Lexicomp, Inc., Hudson, Ohio.
26. Bilici M., Efe H., Koroglu M.A., et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001, 1(64):43-51.
27. Gulseren L., Sulseren S., Hekimsoy Z., et al. Comparison of fluoxetine and paroxetine in Type II diabetes mellitus patients. Arch Med Res 2005, 2(36):159-165.
28. Sauer W.H., Berlin J.A., Kimmel S.E. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003, 108(1):32-36.
29. Jain A.K., Kaplan R.A., Gadde K.M., et al. Bupropion SR versus placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002, 10(10):1049-1056.
30. Laimer M., Kramer-Reinstadler K., RAuchenzauner M., et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006, 67(3):421-424.
31. Nicholas L.M., Ford A.L., Esposito S.M., Ekstrom R.D., Golden R.N. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 2003, 64(8):883-889.
32. Preskorn S.H., Greenblatt D.J., Flockhart D., et al. Comparison of duloxetine, escitalopram and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 2007, 27:28-34.
33. Dent L.A., Orrock M.W. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy 1997, 17:170-172.
34. Benfield P., Ward A. Fluvoxamine: a review of its pharamcodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986, 32:313-334.
35. Walley T., Pirmohamed M., Proudlove C., Maxwell D. Interaction of metoprolol and fluoxetine. Lancet 1993, 341:967-968.
36. Drake W.M., Gordon G.D. Heart block in a patient on propranolol and fluoxetine. Lancet 1994, 343:425-426.
37. McCollum D.L., Greene J.L., McGuire D.K. Severe sinus bradycardia after initiation of bupropion therapy: a probable drug-drug interaction with metoprolol. Cardiovasc Drugs Ther 2004, 18(4):329-330.
38. Sternbach H. Fluoxetine-associated potentiation of calcium-channel blockers. J Clin Psychopharmacol 1991, 11:390-391.
39. Cai W.M., Chen B., Shou Y., Shang Y.D. Fluoxetine impairs the CYP2D6-mediate metabolism of propafenone enantiomers in healthy Chinese volunteers. Clin Pharmacol Ther 1999, 66:516-521.
40. Hirsh-Rokach C., Spectre G., Shai, et al. Differential impact of selective serotonin reuptake inhibitors on platelet response to clopidogrel: a randomized, double-blind, crossover trial. Pharmacotherapy 2015, 35(2):140-147.
41. De Abajo F.J., Garcia-Rodriguez L.A. Risk of upper gastrointestinal tract bleedings associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008, 65:795-803.
42. Covyeou J.A., Jackson C.W. Hyponatremia associated with escitalopram. N Engl J Med 2007, 356:94-95.
43. Abo-Zena R.A., Bobek M.B., Dweik R.A. Hypertensive urgency induced by an interaction of mirtazapine and clonidine. Pharmacotherapy 2000, 20:476-478.
44. Nikolic M., Noorani A., Park G. Interaction between clonidine and escitalopram. Br J Anaesth 2009, 102:567-568.
45. Hauta-Aho M., Tirkkonen T. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med 2009, 41:619-628.
46. Williams R.B. Blood pressure reactivity to psychological stress: a new risk factor for coronary disease?. Hypertension 2006, 47:329-330.
47. Licht C.M., de Geus E.J., Seldenrijk A., et al. Depression is associated with decreased blood pressure, but antidepressant use increases risk for hypertension. Hypertension 2009, 52:631-638.
48. Feighner J.P. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995, 56:574-579.
49. Roose S.P., Dalack G.W., Glassman A.H., et al. Is doxepin a safer 'bicyclic' for the heart?. J Clin Psychiatry 1991, 52:338-341.
50. Kiev A., Masco H.L., Wenger T.L., et al. The cardiovascular effects of bupropion and nortriptyline in depressed outpatients. Ann Clin Psychiatry 1994, 6(2):107-115.
51. Grossman E., Messerli F.H. High blood pressure: a side effect of drugs, poisons, and foods. Arch Intern Med 1995, 155:450-460.
52. Staessen J.A., Thijs L., Fagard R., et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic hypertension in Europe trial investigators. JAMA 1999, 282:539-546.
53. Scalco M.Z., Serro-Azul J.B., Giorgi D., Almeida O.P., Wajngarten M. Effect of nortriptyline on the day-night systolic blood pressure difference in hypertensive and normotensive elderly depressed women. Am J Cardiol 2003, 19:1279-1281.
54. Dowlati Y., Herrmann N., Swardfager W.L., Reim E.K., Lanctot K.L. Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysis. Can J Psychiatry 2010, 55(2):91-98.
55. Carney R.M., Rich M.W., Freedland K.E., et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988, 50:627-633.
56. Anda R., Williamson D., Jones D., et al. Depressed effect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology 1993, 4:285-294.
57. Bush D.E., Ziegelstein R.C., Tayback M., et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2002, 88:337-341.
58. Wulsin L.R., Singal B.M. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med 2003, 65:201-210.
59. De Jonge P., Honig A., van Melle J.P., et al. Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. Am J Psychiatry 2007, 164:1371-1378.
60. Blumenthal J.A., Sherwood A., Babyak M.A., et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J Am Coll Cardiol 2012, 60(12):1053-1063.
61. Roose S.P., Glassman A.H. Antidepressant choice in the patient with cardiac disease: lessons from the cardiac arrhythmia suppression trial (CAST) studies. J Clin Psychiatry 1994, 55:83-87.
62. Glassman A.H. Cardiovascular effects of antidepressant drugs: updated. Int J Clin Psychopharmacol 1998, 13(Suppl. 5):S25-S30.
63. Lichtman J.H., Bigger T., Blumenthal, et al. Depression and coronary heart disease. Recommendations for screening, referral, and treatment. A science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation 2008, 118:1768-1775.
64. Raskind M., Veith R., Barnes R., Gumbrecht G. Cardiovascular and antidepressant effects of imipramine in the treatment of secondary depression in patients with ischemic heart disease. Am J Psychiatry 1982, 139(9):1114-1117.
65. Veith R.C., Raskind M.A., Caldwell J.H., et al. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. N Engl J Med 1982, 306:954-959.
66. Levenson J.L., Friedel R.O. Major depression in patients with cardiac disease: diagnosis and somatic treatment. Psychosomatics 1985, 26(2):91-102.
67. Hamer M., Batty G.D., Seldenrijk A., Kivimaki M. Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. Eur Heart J 2011, 32:437-442.
68. Strik J.J.M.H., Honig A., Lousberg R., et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 2000, 62:783-789.
69. Mohapatra P.K., Kar N., Kar G.C., Behera M. Effectiveness of sertraline in treatment of depression in a consecutive sample of patients with acute myocardial infarction: six month prospective study on outcome. Clin Pract Epidemiol Ment Health 2005, 1:26.
70. Strik J.J.M.H., Honig A., Lousberg R., Cheriex E.C., Van Praag H.M. Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients. Int Clin Psychopharmacol 1998, 13:263-267.
71. Glassman A.H., O'Connor C.M., Califf, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina (the SADHART Trial). JAMA 2002, 288(6):701-710.
72. Lesperance F., Frasure-Smith N., Koszycki D., et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease. The Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA 2007, 297(4):367-379.
73. Berkman L.F., Blumenthal J., Burg M., et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003, 289(23):3106-3116.
74. Taylor C.B., Youngblood M.E., Catellier D., et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005, 62:792-799.
75. Hanash J.A., Hansen B.H., Hansen J.F., et al. Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the depression in patients with coronary artery disease (DECARD) trial. J Cardiovasc Pharmacol 2012, 60:397-405.
76. Pizzi C., Rutjes A.W.S., Costa G.M., et al. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol 2011, 107:972-979.
77. McFarlane A., Kamath M.V., Fallen E.L., et al. Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J 2001, 142(4):617-623.
78. Glassman A.H., Bigger T., Gaffney M., van Zyl L.T. Heart rate variability in acute coronary syndrome patients with major depression. Arch Gen Psychiatry 2007, 64(9):1025-1031.
79. Yeragani V.K., Pesce V., Jayaraman A., Roose S. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry 2002, 52:418-429.
80. Pizzi C., Mancini S., Angeloni L., et al. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther 2009, 86(5):527-532.
81. Jiang W., Velazquez E.J., Kuchibhatla M., et al. Effect of escitalopram on mental stress-induced myocardial ischemia. JAMA 2013, 309(20):2139-2149.
82. 2A receptor as missing link?. Psychosom Med 2003, 65:729-737.
83. Castro V.M., Gallagher P.J., Clements C.C., et al. Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. Br Med J Open 2012, 2:e000544.
84. Labos C., Dasgupta K., Nedjar H., Turecki G., Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. Can Med Assoc J 2011, 183(6):1835-1843.
85. Andrade C., Sandharsh S., Chethan K.B., et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010, 71(12):1565-1575.
86. Whooley M.A. Depression and cardiovascular disease. JAMA 2006, 295(24):2874-2881.
87. Gravely-Witte S., Stewart D.E., Suski N., Grace S.L. The association among depressive symptoms, smoking status and antidepressant use in cardiac outpatients. J Behav Med 2009, 32:478-490.
88. DeGraaf L., Diemont W.L. Chest pain during use of bupropion as an aid in smoking cessation. Br J Clin Pharmacol 2003, 56(4):451-452.
89. Rigotti N.A., Thorndike A.N., Regan S., et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med 2006, 119(12):1080-1087.
90. Tonstad S., Farsang C., Klaene G., et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicenter randomized study. Eur Heart J 2003, 24(10):946-955.
91. Honig A., Kuyper A.M.G., Schene A.H., et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo controlled trial with mirtazapine. Psychosom Med 2007, 69:606-613.
92. Johnson E.M., Whyte E., Mulsant B.H., et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 2006, 14(9):796-802.
93. Roose S.P. Treatment of depression in patients with heart disease. Biol Psychiatry 2003, 54:262-268.
94. Schnabel R.B., Michal M., Wilde S., et al. Depression in atrial fibrillation in the general population. PLoS One 2013, 8(12):e79109.
95. Thompson T.S., Barksdale D.J., Sears S.F., et al. The effect of anxiety and depression on symptoms attributed to atrial fibrillation. Pacing Clin Electrophysiol 2014, 37(4):439-446.
96. Whang W., Kubzansky L.D., Kawachi I., et al. Depression and risk of sudden cardiac death and coronary heart disease in women. Results from the Nurses' Health Study. J Am Coll Cardiol 2009, 53:950-958.
97. Credible Meds Drugs to be avoided by congenital long QT patients Available at:, [Accessed June 10, 2014]. http://www.crediblemeds.org/pdftemp/pdf/CombinedList.pdf.
98. Jolly K., Gammage M.D., Cheng K.K., et al. Sudden death in patients receiving drugs tending to prolong the QT interval. Br J Clin Pharmacol 2009, 68(5):743-751.
99. Castro V.M., Clements C.C., Murphy S.N., et al. QT interval and antidepressant use: a cross-sectional study of electronic health records. Br Med J 2013, 346:1-11.
100. US Food and Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses Available at:, [Accessed June 6, 2014]. http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.
101. Beach S.R., Kostis W.J., Celano C.M., et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014, 75(5):441-449.
102. Zivan K., Pfeiffer P.N., Bohnert A.S., et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry 2013, 170(6):642-650.
103. Medicines and Healthcare Products Regulatory Agency (MHRA) Citalopram and escitalopram: QT interval prolongation: new maximum daily dose restrictions, contraindications and warnings Available at:, [Accessed June 11, 2014]. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON137769.
104. Forest Laboratories Highlights of Lexapro® Prescribing Information 2012.
105. Buff D.D., Brenner R., Kirtane S., Gilboa M. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991, 52:174-176.
106. Ellison J.M., Milofsky J.E., Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1990, 51(9):385-386.
107. Wilting I., Smals O.M., Holwerda N.J., et al. QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine [letter]. Am J Psychiatry 2006, 163:325.
108. Funk J.A., Bostwick J.R. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother 2013, 47(10):1330-1341.
109. Brzozowska A., Werner B. Observation of QTc prolongation in an adolescent girl during fluvoxamine pharmacotherapy. J Child Adolesc Psychopharmacol 2009, 10:591-592.
110. Nia A.M., Dahlem K.M. Clinical impact of fluvoxamine-mediated long QT syndrome. Eur J Clin Pharmacol 2012, 68:109-111.
111. Amin M., Lehmann H., Mirmiran J. A double-blind, placebo-controlled dose-finding study with sertraline. Psychopharmacol Bull 1989, 25(2):164-167.
112. Himmelhoch J.M., Schechtman K., Auchenbach R. The role of trazodone in the treatment of depressed cardiac patients. Psychopathology 1984, 17(Suppl. 2):51-63.
113. Janowsky D., Curtis G., Zisook S., et al. Ventricular arrhythmias possibly aggravated by trazodone. Am J Psychiatry 1983, 140(6):796-797.
114. Aronson M.D., Hafex H. A case of trazodone-induced ventricular tachycardia. J Clin Psychiatry 1986, 47(7):388-389.
115. Vitullo R.N., Wharton J.M., Allen N.B., Pritchett E.L.C. Trazodone-related exercise-induced nonsustained ventricular tachycardia. Chest 1990, 98(1):247-248.
116. Mazur A., Strasberg B., Kusinec J. QT prolongation and polymorphous ventricular tachycardia with trazodone-amiodarone combination. Int J Cardiol 1995, 52:27-29.
117. Levenson J.L. Prolonged QT interval after trazodone overdose. Am J Psychiatry 1999, 156:969a-970a.
118. Pohl R., Bridges M., Rainey J.M., Boudoulas H., Yeragani V. Effects of trazodone and desipramine on cardiac rate and rhythm in a patient with preexisting cardiovascular disease. J Clin Psychopharmacol 1986, 6(6):380-381.
119. Burgess C.D., Hames T.K., Geaoge C.F. The electrocardiographic and anticholinergic effects of trazodone and imipramine in man. Eur J Clin Pharmacol 1982, 23:417-421.
120. Letsas K., Korantzopoulos P., Pappas, et al. QT interval prolongation associated with venlafaxine administration. Int J Cardiol 2006, 109(1):116-117.
121. Stuhec M. Duloxetine-induced life-threatening long AT syndrome. Wien Klin Wochenschr 2013, 125(5-6):165-166.
122. Wernicke J., Lledo A., Raskin J., Kajdasz D.K., Wang F. An evaluation of the cardiovascular safety profile of duloxetine. Findings from 42 placebo-controlled studies. Drug Saf 2007, 30(5):437-455.
123. Health Canada REMERON/REMERON RD (mirtazapine) - abnormal heart rhythm - for health professionals Available at:, [Accessed June 6, 2014]. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/38709a-eng.php.
124. Carnes C.A., Pickworth K.K., Votolato N.A., Raman S.V. Elevated defibrillation threshold with venlafaxine therapy. Pharmacotherapy 2004, 24(8):1095-1098.
125. Wang C.M., Parker C.H., Maxwell R.A. Electrophysiological effects of antidepressants on mammalian hearts and crayfish giant axon. J Cardiovasc Pharmacol 1981, 3:101-112.
126. Smith R.B., Rusbatch B.J. Amitriptyline and heart block. Br Med J 1976, 3:311.
127. Kantor S.J., Bigger J.T., Glassman A.H., Macken D.L., Perel J.M. Imipramine-induced heart block: a longitudinal case study. JAMA 1975, 231:1364-1366.
128. Dietch J.T., Fine M. The effect of nortriptyline in elderly patients with cardiac conduction disease. J Clin Psychiatry 1990, 51(2):65-67.
129. Gambassi G., Incalzi R.A. Atrioventricular blocks associated with citalopram. Am J Geriatr Psychiatry 2005, 13(10):918-919.
130. Isbister G.K., Prior F.H., Foy A. Citalopram-induced bradycardia and presyncope. Ann Pharmacother 2001, 35:1552-1556.
131. Winkler D., Ortner R., Pjrek E., Aschauer H., Kasper S. Trazodone-induced cardiac arrhythmias: a report of two cases. Hum Psychopharmacol Clin Exp 2006, 21:61-62.
132. Irwin M., Spar J.E. Reversible cardiac conduction abnormality associated with trazodone administration. Am J Psychiatry 1983, 140(7):945-946.
133. Shirayama T., Sakamoto T., Sakatani T., et al. Usefulness of paroxetine in depressed men with paroxysmal atrial fibrillation. Am J Cardiol 2006, 97:1749-1751.
134. Sayal K.S., Duncan-McConnell D.A., McConnell H.W., Taylor D.M. Psychotropic interactions with warfarin. Acta Psychiatr Scand 2000, 102:250-255.
135. Joynt K.E., Whellan D.J., O'Connor C.M. Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. J Card Fail 2004, 10:258-271.
136. Jiang W., Alexander J., Christopher E., et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure 2001, 161:1849-1856.
137. Spaderna H., Zahn D., Schulze Schleithoff S., et al. Depression disease severity as correlates of everyday physical activity in heart transplant candidates. Transpl Int 2010, 23:813-822.
138. O'Connor C.M., Jiang W. Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med 2008, 168:2232-2237.
139. Jiang W., Krishnan R.R. Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease. Curr Psychiatry Rep 2004, 6:202-209.
140. Sullivan M., Simon G., Spertus J., Russo J. Depression-related costs in heart failure care. Arch Intern Med 2002, 162:1860-1866.
141. Moraska A.R., Chamberlain A.M., Shah N.D., et al. Depression, healthcare utilization, and death in heart failure. Circ Heart Fail 2013, 6:387-394.
142. Johnson T.J., Basu S. Depression predicts repeated heart failure hospitalizations. J Card Fail 2012, 18:246-252.
143. Woltz P.C., Chapa D.W. Effects of interventions on depression in heart failure: a systematic review. Heart Lung 2012, 41:469-483.
144. O'Hea E., Houseman J., Bedek K., et al. The use of cognitivie behavioral therapy in the treatment of depression for individuals with CHF. Heart Fail Rev 2009, 14(1):13-20.
145. Jimenez J.A., Redwine L.L., Rutledge T.R., et al. Depression ratings and antidepressant use among outpatient heart failure patients: implications for the screening and treatment of depression. Int J Psychiatry Med 2012, 44(4):315-334.
146. Chung M.L., Dekker R., Lennie T.A., Moser D. Antidepressants do not improve event-free survival in patients with heart failure when depressive symptoms remain. Heart Lung 2013, 42:85-91.
147. Diez-Quevedo C., Lupon J., Gonzalez B., et al. Depression, antidepressants, and long-term mortality in heart failure. Int J Cardiol 2013, 167:1217-1225.
148. Tousoulis D., Antoniades C. Selective serotonin reuptake inhibitors modify the effect of beta-blockers on long-term survival of patients with end-stage heart failure and major depression. J Card Fail 2008, 14:456-464.
149. Fosbol E.L., Gislason G.H., Poulsen H.E., et al. Prognosis in heart failure and the value of beta-blockers are altered by the use of antidepressants and depend on the type of antidepressant used. Circ Heart Fail 2009, 2:582-590.
150. Veien K.T., Videbaek L., Schou M., et al. High mortality among heart failure patients treated with antidepressants. Int J Cardiol 2011, 146:64-67.
151. Angermann C.E., Gelbrich G., Stork S., et al. Rationale and design of a randomized, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail 2007, 9:1212-1222.
152. O'Connor C.M., Jiang W. Safety and efficacy of sertraline for depression in patients with heart failure. J Am Coll Cardiol 2010, 56:692-699.
153. Gottlieb S.S., Kop W.J., Thomas S.A., et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heart J 2007, 153:868-873.
154. Roose S.P., Glassman A.H., Attia E., et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998, 155:660-665.
155. Glassman A.H., Johnson L.L., Giardina E.V., et al. The use of imipramine in depressed patients with congestive heart failure. JAMA 1983, 250:1997-2001.
156. Roose S.P., Dalack G.W., Glassman A.H., Woodring S., Walsh B.T., Giardina E.G. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991, 148:512-516.
157. Roose S.P., Glassman A.H., Giardina E.V., et al. Nortriptyline in depressed patients with left ventricular impairment. JAMA 1986, 256(23):3253-3257.
158. Cohn J.B., Wilcox C.S., Goodman L.I. Antidepressant efficacy and cardiac safety of trimipramine in patients with mild heart disease. Clin Ther 1993, 15(1):114-126.